Jubilant Life Sciences is currently trading at Rs. 599.00, up by 9.15 points or 1.55% from its previous closing of Rs. 589.85 on the BSE.
The scrip opened at Rs. 592.00 and has touched a high and low of Rs. 610.85 and Rs. 589.10 respectively. So far 67806 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 655.00 on 27-Sep-2016 and a 52 week low of Rs. 272.50 on 20-Jan-2016.
Last one week high and low of the scrip stood at Rs. 655.00 and Rs. 572.80 respectively. The current market cap of the company is Rs. 9559.26 crore.
The promoters holding in the company stood at 54.02%, while institutions and non-institutions held 26.82% and 19.15% respectively.
Jubilant Pharma (JPL), a 100% subsidiary of Jubilant Life Sciences, has successfully raised $300 million through a sale of unsecured bonds. The bonds have been subscribed at the tight end of the final price guidance offering a yield of 4.875% to investors. The net proceeds of the Notes shall be used to prepay the existing debts of JPL and its subsidiaries, for upstreaming up to $50 million to Jubilant Life Sciences for prepayment of its existing debts and for general corporate purposes. The company received bids over $1 billion. The bonds will be listed on Singapore Stock Exchange. The issuer (JPL) has been rated BB- by- Standard & Poor's Ratings Services (S&P) and Fitch Inc (Fitch) and the issue (the notes) has been rated BB- by S&P and BB by Fitch.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: